TSHA241220P500
- 0.00
- 0.000.00%
Taysha Gene Therapies Newsroom
JMP Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $5
Buy Rating for Taysha Gene Therapies Due to Safer Administration Method and Lower Viral Dose
Taysha Gene Therapies Analyst Ratings
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $8
Taysha Gene Therapies Price Target Maintained With a $6.00/Share by Needham
Taysha Gene Therapies Shares Are Trading Higher. Cantor Fitzgerald Reiterated an Overweight Rating on the Stock.
Hillenbrand Posts Better-Than-Expected Earnings, Joins Beazer Homes, Tapestry, Walt Disney And Other Big Stocks Moving Higher On Thursday
Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $7
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $5
Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $5 to $7.5
Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Taysha Gene Therapies: Promising Developments and Strong Financial Position Support Buy Rating
Taysha Gene Therapies Advances in Rett Syndrome Trials
Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript Summary
Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript
Taysha Gene Therapies | 10-Q: Q3 2024 Earnings Report
Earnings Flash (TSHA) TAYSHA GENE THERAPIES Posts Q3 Revenue $1.79M
Taysha Gene Therapies Q3 2024 GAAP EPS $(0.10) Misses $(0.09) Estimate, Sales $1.788M Beat $1.648M Estimate
Taysha Gene Therapies | 8-K: Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update